Clinical Trial for Potential Degenerative Cervical Myelopathy Drug Announced
According to a story from Market Screener, the biopharmaceutical company MediciNova, Inc., recently announced its intention to begin a Phase 2/3 clinical trial for its product MN-166. MN-166, also known…